Related Experiment Video
Updated: Feb 20, 2026

An Ex vivo Mast Cell Degranulation Assay using Crude Peritoneal Exudate Cells and Natural Antigen Stimulation
Published on: April 27, 2021
Tussilagone inhibits MRGPRX2-mediated mast cell degranulation and suppresses pseudo-allergic reactions
Pingping Yan1, Tingting Huang2, Mawusse K I Attiogbe2
1Department of Pharmacology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi 710061, China; Department of Pharmacy, Xi'an Children's Hospital, Xi'an Jiaotong University, Xi'an 710003, China.
Abstract:
Mas-related G protein-coupled receptor X2 (MRGPRX2) is a crucial target in pseudo-allergic reactions. Tussilagone (Tus), the main bioactive component derived from Tussilago farfara, has anti-inflammatory effects, but its potential inhibitory effects on pseudo-allergic responses remain unclear. This research aimed to evaluate the inhibitory role of Tus on pseudo-allergic reactions and its underlying mechanism. In vivo Systemic pseudo-allergic reactions and passive cutaneous anaphylaxis (PCA) models were established to assess the effects of Tus. In vitro, mast cell (LAD2) degranulation, inflammatory cytokine release, and signaling pathway protein expression were assessed. Calcium influx was measured in MRGPRX2-expressing HEK293 cells. The results showed that Tus significantly attenuated Tween 80- and substance P (SP)-induced systemic pseudo-allergy and PCA reactions. It also suppressed mast cell degranulation and decreased production of tumor necrosis factor-alpha (TNF-α), Interleukin-8 (IL-8) and monocyte chemotactic protein-1 (MCP-1). In MRGPRX2-expressing HEK293 cells, Tus suppressed Tween 80- and SP-induced Ca2+ influx. Mechanistically, Tus inhibited tolimidone-induced Lyn kinase activation and suppressed SP-and Tween 80-induced β-hexosaminidase release, exhibiting an inhibitory profile comparable to that of the Lyn/Btk antagonist bosutinib. Additionally, Tus attenuated the phosphorylation levels of MRGPRX2 downstream signal molecules, including Btk, PLCγ1, PKC, p38 MAPK, IκB-α and NF-κB (p65). In conclusion, Tus attenuates SP-and Tween 80-induced mast cell activation and pseudo-allergic reactions by targeting the Lyn/Btk/PLCγ1 and p38/NF-κB pathways, highlighting its therapeutic potential for pseudo-allergy.
More Related Videos
Related Concept Videos
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Allergic Drug Reactions
Antiasthma Drugs: Muscarinic Receptor Antagonists
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Allergic Reactions
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

